Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • CSL continues rally after strong FY26 results and announces share buyback

    CSL reported FY26 total revenue of $15.8bn and an adjusted net profit after tax and depreciation and amortization of $3.1bn, both slightly above revised analyst expectations. The company expects adjusted earnings growth of around 5% for FY27 and announced a new share buyback program of A$1.1bn. Analysts subsequently raised several price targets; UBS, CLSA and Morgan Stanley upgraded their ratings, supported by stronger plasma trends, about $176m in cost savings and greater strategic flexibility following the spin-off of Seqirus. » Altro su de.investing.com


  • CSL forecasts return to growth and launches A$1.1bn share buyback - shares at 6.5‑month high

    CSL raised its outlook for fiscal 2027 and now expects currency‑adjusted growth in adjusted net profit after tax of around 5%, well above consensus of about 2%. For fiscal 2026 the company reported revenue of US$15.8bn, adjusted NPATA of US$3.1bn (−2%) and a reported net loss of US$2.6bn after one‑off impairments related to CSL Vifor. CSL also announced a A$1.1bn share buyback program, which lifted the share price by about 5% to A$165.88. » Altro su de.investing.com


  • CSL rises 16.4% after results and outlook

    CSL called 2026 a “transition year”, reporting revenue of $15.8 billion (currency‑adjusted -1%) and an adjusted NPAT‑A of $3.1 billion, while a statutory loss of $2.6 billion was caused by $6.0 billion of restructuring and impairments. Investors focused on a strong operating cash flow of $3.5 billion, a new $1.1 billion AUD share buyback program and the outlook for around 5% adjusted NPAT growth in 2027 with largely stable revenue. CSL Behring is expected to return to mid‑single‑digit revenue growth in the medium term, while Vifor, as the biggest drag for 2027, expects revenue to fall by about 25%. The stock jumped 16.4% after the announcement as the market put more weight on the outlook, cash flows and capital returns than on the accounting loss. » Altro su de.investing.com


  • CSL reports billion-dollar write-downs and lowers guidance – shares plunge

    Biotech company CSL announces billion-dollar write-downs and lowers its guidance, triggering a sharp share price fall. Investors fear consequences for competition in the mRNA market, and BioNTech is mentioned as a potential beneficiary. » Altro su finanzen.net


  • CSL reports 81% profit decline after $1.1bn impairments – shares plunge

    CSL reported a reported net profit decline of 81% to $401m in the first half of 2026 after one-off impairments totaling $1.1bn. Adjusted NPATA rose 7% to $1.9bn on revenue of $8.3bn (+4%). Management confirmed the full-year guidance, announced an increase of the share buyback to $750m and target cost savings of $500–550m by FY2028; the stock fell sharply after the announcement and is trading near its 52-week low. » Altro su de.investing.com

Nel 2026, CSL ha già distribuito 2,48 € di dividendi. L'ultimo pagamento è avvenuto a ottobre.

Dati finanziari

Nell'ultimo trimestre, CSL ha registrato ricavi pari a 6,39 Mld € e un utile netto di -2,57 Mld €

(EUR) giugno 2026
YoY
Ricavi 6,39 Mld -
Utile lordo 2,84 Mld -
Utile netto -2,57 Mld -
EBITDA 1,69 Mld -

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
56,02 Mld €
Numero di azioni
479,88 Mln
Massimo/minimo a 52 settimane
129,08 € - 58,10 €
Rendimento da dividendo
2,02%
Dividendi TTM
2,48 €
Beta
0,08
Rapporto P/E
-25,36
Rapporto PEG
0,14
Rapporto P/B
4,34
Rapporto P/S
4,09

Profilo aziendale

CSL Limited ricerca, sviluppa, produce, commercializza e distribuisce prodotti biofarmaceutici e prodotti affini in Australia, Stati Uniti, Germania, Regno Unito, Svizzera, Cina e a livello internazionale. La società opera attraverso due segmenti, CSL Behring e Seqirus. Il segmento CSL Behring offre terapie plasmatiche, come prodotti plasmatici e ricombinanti per il trattamento dell'immunodeficienza, dei disturbi emorragici, dell'angioedema ereditario, del deficit di alfa-1 antitripsina e dei disturbi neurologici. Questo segmento conduce inoltre ricerche su terapie plasmatiche e non plasmatiche e riceve licenze e royalty dalla commercializzazione della proprietà intellettuale. Il segmento Seqirus produce e distribuisce prodotti bioterapeutici non plasmatici e sviluppa prodotti legati all'influenza. CSL Limited è stata fondata nel 1916 e ha sede a Parkville, in Australia.

Nome
CSL
CEO
Gordon Naylor DipCompSc
Sede centrale Melbourne, vic
Australia
Sito web
Settore
Sanità
Industria
Biotecnologia
Quotazione in borsa
01/06/1994
Dipendenti 29.000

Simboli di borsa

Borsa Simbolo
Pnk
CMXHF
Australian Securities Exchange Ltd
CSL.AX
Frankfurt
CSJ.F
Düsseldorf
CSJ.DU
Hamburg
CSJ.HM
SIX
CSL.SW
München
CSJ.MU
🍪

Parqet  usa i cookie. Scopri di più